Journal of Diabetes Research最新文献

{"title":"Association Between Sodium-Glucose Cotransporter-2 Inhibitors and Sepsis Risk in Patients With Type 2 Diabetes Mellitus.","authors":"Chun-Ying Wu, Chih-Cheng Lai, Chung-Han Ho, Yu-Cih Wu, Kuang-Ming Liao, Jhi-Joung Wang, Ding-Chau Wang, Fu-Wen Liang","doi":"10.1155/jdr/1437417","DOIUrl":"10.1155/jdr/1437417","url":null,"abstract":"<p><strong>Aims: </strong>This retrospective study is aimed at evaluating the effect of SGLT2 inhibitors (SGLT2i) on the risk of sepsis among patients with Type 2 diabetes mellitus (T2DM).</p><p><strong>Materials and methods: </strong>An active-comparator new user design was utilized based on Taiwan's National Health Insurance Research Database. Adult patients diagnosed with T2DM between 2017 and 2020 who initiated either SGLT2i or DPP-4 inhibitors (DPP-4i) were included. After 1:2 matching by age, sex, and Charlson Comorbidity Index, the study enrolled 34,672 SGLT2i users and 69,344 DPP-4i users. The primary outcome was sepsis, with secondary outcomes including septic shock, organ dysfunction, and mortality. Hazard ratios (HRs) were estimated using Cox proportional hazards regression.</p><p><strong>Results: </strong>SGLT2i users had a significantly lower risk of sepsis than DPP-4i users (10.1% vs. 15.5%; adjusted HR [aHR]: 0.77; 95% CI: 0.74-0.81). The risk of septic shock and mortality in SGLT2i users was also reduced by 30% (aHR: 0.70; 95% CI: 0.57-0.87) and 40% (aHR: 0.60; 95% CI: 0.54-0.66), respectively, compared with that of DPP-4i users.</p><p><strong>Conclusions: </strong>The findings suggest that SGLT2i is associated with a significantly lower risk of sepsis, septic shock, and mortality compared with that of DPP-4i in patients with T2DM.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"1437417"},"PeriodicalIF":3.5,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Systemic Factors in the Progression to Vision-Threatening Diabetic Retinopathy in a New Mexican Patient Population with Type 2 Diabetes: Glycemic Control Is Not Enough.","authors":"Rushi N Mankad, Lauren Marek, Gabriella Acosta, Andrea P Cabrera, Finny Monickaraj, Clifford Qualls, Arup Das","doi":"10.1155/jdr/7203748","DOIUrl":"10.1155/jdr/7203748","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study is to identify associative factors of vision threatening complications of diabetic retinopathy (DR), including proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) in a New Mexican patient population with Type 2 diabetes featuring a high proportion of Hispanic and American Indian patients.</p><p><strong>Methods: </strong>In a retrospective, case-control, cross-sectional study, we performed both univariate and multivariate logistic regression testing of systemic factors for association among patients with nonproliferative diabetic retinopathy (NPDR) without DME, NPDR with DME, and PDR. We also used receiver operating characteristic (ROC) curves to understand how reliable glycemic control is at predicting DR end-complications.</p><p><strong>Results: </strong>Among our 584 patients, 172 were diagnosed with NPDR without DME, 293 with PDR, and 119 with NPDR with DME. A total of 25% of patients with NPDR without DME had poor glycemic control (HbA1c levels of ≥ 9.0%). Similarly, 10% of PDR and 7% of NPDR with DME patients had good glycemic control (HbA1c levels ≤ 7.0%), despite their advanced eye disease. For patients with PDR, we identified significant independent associations with microalbuminuria and macroalbuminuria, Hispanic ethnicity, duration of diabetes, and the use of insulin and beta-blocker medications. In NPDR with DME patients, significant associations were noted with microalbuminuria and macroalbuminuria, HbA1c, GFR, and beta-blocker medications. The hemoglobin A1c level was not significantly associated with PDR but was significantly associated with NPDR with DME. The ROC curve analysis indicated poor predictability for the HbA1c model concerning the presence of PDR (AUC = 0.640) and NPDR with DME (AUC = 0.640).</p><p><strong>Conclusions: </strong>This study suggests that glycemic exposure alone is not a good enough predictor of DR progression. Other diabetic microvascular complications such as nephropathy, in addition to race/ethnicity with differing genetic associative factors, may also play a role in the multifactorial progression through DR phenotypes.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"7203748"},"PeriodicalIF":3.5,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12775827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross-Sectional and Sex-Stratified Analyses\".","authors":"","doi":"10.1155/jdr/9803941","DOIUrl":"10.1155/jdr/9803941","url":null,"abstract":"","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e9803941"},"PeriodicalIF":3.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13213330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148031378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splice Isoforms of the Apoptosis Gene BCL-X Have Opposing Effects in Diabetic Kidney Disease: Potential Treatment Target and Prognostic Value.","authors":"Megan Stevens, Monica L Ayine, Kim Gooding, Angela Shore, Pedro Marqueti, Sebastian Oltean","doi":"10.1155/jdr/2840106","DOIUrl":"10.1155/jdr/2840106","url":null,"abstract":"<p><p>In recent years, the importance of alternative splicing (AS) of certain genes in the nature and progression of diabetic nephropathy (DN) has been studied. We report a novel AS event observed in the diabetic kidney-AS of the apoptosis gene BCL-X to increase the proapoptotic BCL-XS and decrease the antiapoptotic BCL-XL. This study is aimed at further investigating the role of this novel AS event in the pathogenesis of DN. To characterize important splicing events in progression of DN, human glomerular endothelial cells (GEnCs) were exposed to a diabetic environment for 1 week, and RNAseq was performed. Although several splicing events were discovered, we focused on the apoptosis gene BCL-X in the present study. In GEnCs, an upregulation of the BCL-XS/BCL-XL ratio was observed, resulting in an increase in GEnC apoptosis. An upregulation of IL-6 was also observed, and treatment with IL-6 alone induced a dose-dependent shift in BCL-X splicing to promote expression of the proapoptotic BCL-XS. Furthermore, we identified certain splicing factors, SF3B1 and PTBP1, involved in BCL-X splicing regulation. Overexpression of the antiapoptotic BCL-XL isoform rescued apoptosis, suggesting a possible therapeutic avenue. In patients, an increase in the proapoptotic BCL-XS in urinary RNA correlated with a decline in the glomerular filtration rate, whereas in blood it correlated with the level of albuminuria. There is an increase in the proapoptotic BCL-XS isoform in the diabetic glomerular endothelium, resulting in increased GEnC apoptosis. Increased BCL-XS expression correlates with markers of renal function decline, implicating this AS event as a potential biomarker for DN severity. Furthermore, a switch of isoforms from BCL-XS to BCL-XL is highlighted as a novel therapeutic strategy.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e2840106"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secretory Acid Sphingomyelinase in Children and Adolescents With Type 1 Diabetes.","authors":"Chiara Mameli, Alice Bolchini, Cristina Ferrigno, Paulina Roux Biejat, Alessandro Arcari, Silvia Zecchini, Alessandra Napoli, Francesca Chiara Redaelli, Maddalena Macedoni, Agnese Petitti, Gianvincenzo Zuccotti, Emilio Clementi, Cristiana Perrotta","doi":"10.1155/jdr/5569377","DOIUrl":"10.1155/jdr/5569377","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;The activity of acid sphingomyelinase (ASMase), a key enzyme in sphingolipid metabolism, has been found to be increased in a variety of human diseases. Studies conducted on animal and cellular models showed that sphingolipids and ASMase play a central role in the pathogenesis of type 1 diabetes (T1D) and T1D-related vascular damage. Currently, no studies have investigated the role of ASMase activity in pediatric patients with T1D. Therefore, we conducted a cross-sectional study to evaluate the activity of the secretory form of ASMase (S-ASMase) in the serum of patients with T1D aged 2-16 years in comparison with a control group (healthy subjects matched for age, gender, and pubertal stage).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;We recruited children and adolescents affected by T1D (including patients with new-onset and established T1D) aged 2-16 years and healthy normal-weight subjects with normal timing of puberty (matched for age, gender, and pubertal stage), who were consecutively admitted-as outpatients-to our institution for screening purposes. Serum lipid profile, glycated hemoglobin (HbA1c), and urine albumin-creatinine ratio (uACR) were assessed in all T1D patients. S-ASMase activity was measured in all study participants through a colorimetric assay.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In total, 68 T1D patients and 51 healthy controls were recruited in this study. None of the T1D patients had T1D-related complications. No difference in S-ASMase activity was observed between subjects with T1D and healthy controls. However, when T1D patients were stratified according to the duration of diabetes, we found a significantly higher activity of S-ASMase in patients with new-onset T1D (recruited within 1 week after the disease diagnosis) as compared to that observed in patients with established T1D. In all patients with T1D, S-ASMase activity correlated positively with HbA1c and triglyceride levels, while it correlated negatively with total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) levels. However, there were no significant differences in S-ASMase activity between T1D patients with new-onset disease who presented with diabetic ketoacidosis (DKA; n = 12) and T1D patients with new-onset disease who did not present with DKA (n = 13).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Our study evaluated, for the first time, the in vivo activity of S-ASMase in a pediatric cohort of patients with T1D. In pediatric patients with new-onset T1D, we found a significantly higher S-ASMase activity as compared to that observed in patients with established T1D. In all T1D patients, the positive correlation between S-ASMase activity, HbA1c, and triglyceride levels, as well as the negative correlation between S-ASMase activity and HDL-C levels, suggests a potential role played by sphingolipids in T1D pathophysiology. Further mechanistic studies are needed to better elucidate the role of S-ASMase in patients with T1D","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e5569377"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Multi-Omics Analysis Identifies PDK4 and ACOT1 as Metabolic Hub Genes Associated With Myocardial Fibrosis in Diabetic Cardiomyopathy.","authors":"Huan Liu, Guanming Qi, Shengrong Ouyang, Feifei Ma","doi":"10.1155/jdr/1952672","DOIUrl":"10.1155/jdr/1952672","url":null,"abstract":"<p><p>Diabetic cardiomyopathy (DCM) is a critical pathological driver of heart failure in diabetic patients, primarily characterized by progressive myocardial fibrosis. Nevertheless, the core molecular network linking upstream metabolic dysregulation to the aberrant activation of downstream cardiac fibroblasts remains largely elusive. In this study, we combined in vivo and in vitro approaches with bioinformatics analysis. A high-fat diet-induced mouse model of diabetic myocardial fibrosis was established, and transcriptome sequencing was performed to screen for hub genes, which were subsequently validated in two independent DCM datasets. Single-cell RNA sequencing revealed that PDK4 and ACOT1 were upregulated in cardiac fibroblasts under pathological conditions. In vitro experiments confirmed that high glucose induced the expression of PDK4, ACOT1, and fibrotic markers in human primary cardiac fibroblasts. Molecular docking predicted a potential interaction between PDK4 and ACOT1. Collectively, our findings identify PDK4 and ACOT1 as evolutionarily conserved metabolic hub genes associated with myocardial fibrosis in DCM, suggesting a putative \"metabolism-fibrosis axis\" and providing potential therapeutic targets.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e1952672"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicaid CGM Barriers in Blind/Low Vision and Deaf/Hard of Hearing Populations.","authors":"Michelle L Litchman, Andrew P Bray, Jacee S Moore, Chinue Wilford, Allyson S Hughes","doi":"10.1155/jdr/3621409","DOIUrl":"10.1155/jdr/3621409","url":null,"abstract":"<p><p>Continuous glucose monitors (CGMs) are essential tools for diabetes management; however, many state Medicaid programs do not have standardized, inclusive policies that ensure equitable access to CGMs for blind/low vision (BLV) and deaf/hard of hearing (DHH) populations, driving disparities across the United States and its territories. This policy analysis examines the barriers and facilitators to Medicaid CGM coverage for BLV and DHH populations, specifically in Medicaid and non-Medicaid expansion states, and patient choice in CGM device selection. CGM barrier language existed in 9.6% of states and U.S. territories, preventing BLV and DHH populations from accessing CGM. Facilitator language was present in 5.8% of states and U.S. territories, advocating for equitable access to CGMs for BLV individuals but not DHH individuals. Given the limitations of CGM alarms, this paper also emphasizes the need for Medicaid to cover secondary devices that provide needed haptic, visual, and audible alarms as necessary accessibility tools rather than optional add-ons. These devices are integral to ensuring a safe and independent CGM use for BLV and DHH individuals. Policy changes that prioritize health equity, framing CGM access as both a usability issue and a matter of eligibility for all Medicaid beneficiaries, is crucial.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e3621409"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13156407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-Stratified Association of Serum Uric Acid With Multisite Bone Mineral Density Among Inpatients With Type 2 Diabetes: A Cross-Sectional Study.","authors":"Shangjian Li, Weihong Lu, Xiumei Luo, Kai Wang, Jingqi Zhou, Silan Zheng, Ning Chen","doi":"10.1155/jdr/4367218","DOIUrl":"10.1155/jdr/4367218","url":null,"abstract":"<p><strong>Objective: </strong>This study sought to investigate the correlation between serum uric acid (SUA) levels and bone mineral density (BMD) among patients with Type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>A single-center retrospective cross-sectional analysis was performed. A total of 249 hospitalized patients with T2DM (147 men and 102 postmenopausal women) were recruited from Zhongshan Hospital (Xiamen), Fudan University, between June 2024 and June 2025. Baseline clinical characteristics were first compared between patients with normal BMD and those with osteopenia or osteoporosis. All participants were subsequently stratified into a normal uric acid (NUA) group and a hyperuricemia (HUA) group based on SUA concentrations. BMD measurements at the femoral neck, total hip, and lumbar spine were compared across the two groups. Multivariate logistic regression analysis was applied to determine independent factors associated with the risk of osteopenia and osteoporosis.</p><p><strong>Results: </strong>Of the 249 enrolled participants, 178 (71.5%) were diagnosed with osteopenia or osteoporosis. Relative to patients with normal BMD, individuals with osteopenia/osteoporosis were older, had a higher proportion of female cases, exhibited elevated osteocalcin (OCN) levels and increased fracture risk, and presented significantly lower body mass index (BMI), estradiol (E2), and SUA levels. In the overall cohort, as well as in male and postmenopausal female subgroups, higher SUA levels were significantly and positively correlated with higher BMD at all three skeletal sites (all p < 0.05). Multivariate logistic regression demonstrated that OCN served as an independent risk factor for osteopenia and osteoporosis, whereas BMI, E2, and SUA served as independent protective factors against these bone disorders (all p < 0.05).</p><p><strong>Conclusion: </strong>Elevated SUA levels are correlated with higher BMD and a reduced risk of osteopenia and osteoporosis in T2DM patients. BMI, E2, OCN, and SUA act as independent predictors of bone status in this patient population. Routine SUA testing may facilitate the identification of T2DM patients at high risk of osteopenia and osteoporosis.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e4367218"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13463739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148712751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Joint Impact of METS-VF and Functional Limitation on Cardiometabolic Multimorbidity Risk.","authors":"Xuhui Chen, Ying Wang, Jiaofen Wu, Yulian He, Huihui Chen, Honghua Ye, Jianhui Liu","doi":"10.1155/jdr/6450867","DOIUrl":"10.1155/jdr/6450867","url":null,"abstract":"<p><strong>Background: </strong>Cardiometabolic multimorbidity (CMM) has emerged as a primary public health challenge, significantly increasing mortality risk and reducing quality of life. Although the metabolic score for visceral fat (METS-VF) and functional limitation are recognized individually as risk factors for cardiometabolic health, the bidirectional relationship between functional limitation and CMM suggests complex underlying mechanisms. However, research investigating the independent and joint effects of METS-VF (representing visceral obesity) and functional limitation on the risk of CMM onset is lacking. This study is aimed at systematically elucidating these associations to provide evidence for targeted interventions.</p><p><strong>Methods: </strong>This prospective cohort study utilized data from the China Health and Retirement Longitudinal Study (CHARLS). A total of 8140 participants were included in the cross-sectional analysis, and a sub-cohort of 5356 individuals free of CMM at baseline was followed longitudinally. CMM was defined as the coexistence of at least two cardiometabolic diseases: heart disease, diabetes, stroke, or hypertension. Functional limitation was assessed using activities of daily living (ADL) and instrumental ADL (IADL) scales. Multivariable Cox proportional hazards regression and restricted cubic spline (RCS) analysis were employed to evaluate the association between METS-VF, functional limitations, and CMM incidence.</p><p><strong>Results: </strong>During the follow-up period, METS-VF demonstrated a nonlinear positive dose-response relationship with CMM risk. In the longitudinal analysis, participants in the high METS-VF group (defined by the RCS inflection point) exhibited a significantly elevated risk of developing CMM compared to the low-risk group (HR = 1.77, 95% CI: 1.39-2.26) after adjusting for confounders. Continuous functional limitations were also independently associated with incident CMM (HR = 1.12, 95% CI: 1.08-1.16). Notably, a joint effect was observed; participants with both high METS-VF and functional limitations faced the highest risk (HR = 2.43, 95% CI: 1.78-3.31). Receiver operating characteristic (ROC) analysis indicated that the combined model incorporating both factors achieved superior predictive accuracy (AUC = 0.680) compared to single-factor models.</p><p><strong>Conclusion: </strong>METS-VF and functional limitations are strong independent predictors of CMM, and their simultaneous presence exerts a significant joint effect on disease risk. The integration of METS-VF and functional assessment into clinical practice can enhance CMM risk stratification and facilitate the early identification of vulnerable high-risk subgroups.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e6450867"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13261289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148226006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Levels of Remnant Cholesterol as Potential Biomarkers for Predicting Gestational Diabetes: A Systematic Review.","authors":"Fatemeh Abdi, Fatemeh Alsadat Rahnemaei, Fatemeh Khosravani, Farzad Sadri, Yaser Mohammadi","doi":"10.1155/jdr/9942007","DOIUrl":"10.1155/jdr/9942007","url":null,"abstract":"<p><strong>Objectives: </strong>Gestational diabetes mellitus (GDM) is a common pregnancy complication with serious consequences for both mother and child. Current diagnostic methods are invasive and limited. The present study was conducted to evaluate circulating remnant cholesterol (RC) as a potential predictive and diagnostic biomarker for GDM.</p><p><strong>Methods: </strong>The present study was conducted following PRISMA guidelines. Databases including Scopus, PubMed, Web of Science (WoS), Embase, ProQuest, Cochrane, and Google Scholar were searched up to August 2025 using standardized keywords. The search results were independently screened by two researchers in two stages. The quality of included articles was assessed using the Newcastle-Ottawa Scale (NOS).</p><p><strong>Results: </strong>Finally, 11 studies were included in this systematic review. Women who developed GDM had higher circulating RC levels than those who did not. Overall, higher RC levels in early pregnancy were linked to a greater risk of GDM, with even small increases in RC translating into a higher likelihood of the condition. Although the strength of this link varied across studies and one suggested a possible protective effect, the evidence points to a fairly consistent association.</p><p><strong>Conclusions: </strong>This systematic review indicates that circulating RC is a promising candidate biomarker for early risk stratification of GDM. RC levels in the first trimester show a significant positive association with GDM risk, highlighting its potential for clinical integration. Further studies are needed to define cutoffs, validate across populations, and confirm real-world applicability.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 1","pages":"e9942007"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}